Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial Authors Xiaofan Liu (ORCID: https://orcid.org/0000-0002-9911-4491) Ying Chi (ORCID: https://orcid.org/0009-0007-9262-0408) Ting Sun (ORCID: https://orcid.org/0000-0003-3997-6062) Xingli Zhao (ORCID: https://orcid.org/0000-0002-7731-170X) H. Dong (ORCID: https://orcid.org/0000-0002-1783-711X) Zeping Zhou (ORCID: https://orcid.org/0000-0002-7698-7695) Renchi Yang (ORCID: https://orcid.org/0000-0003-3741-8518) Xinyue Dai (ORCID: https://orcid.org/0000-0001-8684-2118) Yanmei Xu (ORCID: https://orcid.org/0000-0003-4607-9781) Xiaolei Pei (ORCID: https://orcid.org/0000-0002-6491-3816) Wenjing Gu (ORCID: https://orcid.org/0000-0003-1604-7666) Feng Xue (ORCID: https://orcid.org/0000-0002-5947-3924) Mankai Ju (ORCID: https://orcid.org/0000-0002-8784-9116) Wei Liu (ORCID: https://orcid.org/0000-0003-1792-6048) Rongfeng Fu (ORCID: https://orcid.org/0000-0001-5442-1028) Zhenyu Yan Huiyuan Li (ORCID: https://orcid.org/0000-0003-3242-1742) Lei Zhang (ORCID: https://orcid.org/0000-0001-7769-7377) Hu Zhou Yunfei Chen (ORCID: https://orcid.org/0000-0001-7309-8545) Zhengjie Hua Wentian Wang Jiawen Dai Institutions Chinese Academy of Medical Sciences & Peking Union Medical College (CN) Kunming Medical University (CN) Zhengzhou University (CN) North China University of Science and Technology Affiliated Hospital (CN) Tianjin People's Hospital (CN) Henan Cancer Hospital (CN) Institute of Hematology & Blood Diseases Hospital (CN) Funders National Natural Science Foundation of China Chinese Academy of Medical Sciences Explore the Global Research Space Interactive Map